TP53 and breast carcinoma: In TP53 PV carriers, estrogen-ER signaling might affect the early onset of breast cancer; both ER and HER2 signaling are drivers of cell proliferation and disease progression in breast cancer, and their crosstalk might facilitate breast cancer development; however, further investigations are required to clarify these relationships.